Reiher FK - Search Results

1

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Reiher FK, et al. Int J Cancer. 2002 Apr 10;98(5):682-9. doi: 10.1002/ijc.10247. Int J Cancer. 2002. PMID: 11920636

2

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.

Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Doll JA, et al. Among authors: reiher fk. Prostate. 2001 Dec 1;49(4):293-305. doi: 10.1002/pros.10025. Prostate. 2001. PMID: 11746276

3

p53 and microvessel density in primary resection specimens of superficial bladder cancer.

Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SC. Reiher F, et al. J Urol. 2002 Mar;167(3):1469-74. J Urol. 2002. PMID: 11832772

4

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Volpert OV, et al. Nat Med. 2002 Apr;8(4):349-57. doi: 10.1038/nm0402-349. Nat Med. 2002. PMID: 11927940

5

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N. Jiménez B, et al. Oncogene. 2001 Jun 7;20(26):3443-8. doi: 10.1038/sj.onc.1204464. Oncogene. 2001. PMID: 11423995

6

The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.

Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. Reiher FK, et al. J Urol. 2001 Jun;165(6 Pt 1):2075-81. doi: 10.1097/00005392-200106000-00073. J Urol. 2001. PMID: 11371931

7

Antiangiogenic approaches to renal cell carcinoma : assays for inhibitors and clinical trials.

Campbell SC, Reiher FK, Smith ND Jr. Campbell SC, et al. Among authors: reiher fk. Methods Mol Med. 2001;53:277-98. doi: 10.1385/1-59259-144-2:277. Methods Mol Med. 2001. PMID: 21318802

8

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F. Filleur S, et al. Genes Dev. 2001 Jun 1;15(11):1373-82. doi: 10.1101/gad.193501. Genes Dev. 2001. PMID: 11390357 Free PMC article.

9

Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.

Klatte T, Böhm M, Nelius T, Filleur S, Reiher F, Allhoff EP. Klatte T, et al. BJU Int. 2007 Jul;100(1):209-14. doi: 10.1111/j.1464-410X.2007.06871.x. Epub 2007 Apr 8. BJU Int. 2007. PMID: 17428240

10

An unusual case of Birt-Hogg-Dube syndrome with renal involvement.

Janitzky A, Reiher F, Porsch M, Grube C, Evert M, Liehr UB. Janitzky A, et al. Urol J. 2008 Fall;5(4):272-4. Urol J. 2008. PMID: 19101904 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters